Phase 1
Pathogens for antimicrobial resistance may still be a bit off peoples’ radar, but the lessons from unpreparedness of COVID-19 are in the mind of Qpex.
Of these six patients, three had a partial response (PR) with their tumors shrinking by more than 30%.
Mirati and Sanofi will assess the combination of adagrasib and SAR442720 in a Phase I/II study in patients with previously treated non-small-cell lung cancer who express KRASG12C mutations.
Allogene placed its study on hold after sending a notification to the U.S. FDA about a chromosomal abnormality in its ALPHA2 study patient.
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
The ability to utilize one protein degrader against a whole host of diseases drives Kymera’s strategy when choosing protein targets.
It was a busy week for clinical trial news. Here’s a look.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
PRESS RELEASES